Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
UBS
AstraZeneca
US Department of Justice
Boehringer Ingelheim
Deloitte
QuintilesIMS
Harvard Business School

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,066,856

« Back to Dashboard

Which drugs does patent 9,066,856 protect, and when does it expire?

Patent 9,066,856 protects OMIDRIA and is included in one NDA.

Protection for OMIDRIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-four countries.
Summary for Patent: 9,066,856
Title:Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
Inventor(s): Demopulos; Gregory A. (Mercer Island, WA), Shen; Hui-rong (Bothell, WA), Tedford; Clark E. (Poulsbo, WA)
Assignee: Omeros Corporation (Seattle, WA)
Application Number:14/061,039
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 9,066,856

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Omeros OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388-001 May 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,066,856

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,486,406 Stable preservative-free mydriatic and anti-inflammatory solutions for injection ➤ Sign Up
9,855,246 Stable preservative-free mydriatic and anti-inflammatory solutions for injection ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
AstraZeneca
Citi
Boehringer Ingelheim
Merck
Cantor Fitzgerald
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.